Phillip Scheinberg

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Br J Haematol 133:622-7. 2006
  2. ncbi request reprint Alloreactive T cell clonotype recruitment in a mixed lymphocyte reaction: implications for graft engineering
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892 1202, USA
    Exp Hematol 34:788-95. 2006
  3. ncbi request reprint Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Br J Haematol 133:606-11. 2006
  4. pmc Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Blood 109:3219-24. 2007
  5. pmc The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 114:5071-80. 2009
  6. pmc Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
    Ronan Desmond
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
    Blood 123:1818-25. 2014
  7. pmc Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells
    J Joseph Melenhorst
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Biol Blood Marrow Transplant 17:800-9. 2011
  8. pmc Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Haematologica 94:348-54. 2009
  9. pmc Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Blood 119:345-54. 2012
  10. pmc High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow
    J Joseph Melenhorst
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 113:2238-44. 2009

Detail Information

Publications44

  1. ncbi request reprint Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Br J Haematol 133:622-7. 2006
    ..In our study, the response rate in refractory patients was inferior to what has been previously reported...
  2. ncbi request reprint Alloreactive T cell clonotype recruitment in a mixed lymphocyte reaction: implications for graft engineering
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892 1202, USA
    Exp Hematol 34:788-95. 2006
    ..To better understand the alloresponse between HLA-identical related pairs, we characterized the alloreactive T cells generated in a mixed lymphocyte reaction (MLR) assay system...
  3. ncbi request reprint Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Br J Haematol 133:606-11. 2006
    ..Over half of the relapses occurred during MMF administration. Despite a strong theoretical rationale for its use, MMF did not result in the improvement of response or relapse rates when compared with historical standard h-ATG/CsA...
  4. pmc Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Blood 109:3219-24. 2007
    ....
  5. pmc The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 114:5071-80. 2009
    ....
  6. pmc Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
    Ronan Desmond
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
    Blood 123:1818-25. 2014
    ..This study is registered at www.clinicaltrials.gov as #NCT00922883. ..
  7. pmc Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells
    J Joseph Melenhorst
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Biol Blood Marrow Transplant 17:800-9. 2011
    ....
  8. pmc Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Haematologica 94:348-54. 2009
    ....
  9. pmc Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Blood 119:345-54. 2012
    ..We conclude that alemtuzumab is effective in SAA, but best results are obtained in the relapsed and refractory settings. The present trials were registered at www.clinicaltrials.gov as NCT00195624, NCT00260689, and NCT00065260...
  10. pmc High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow
    J Joseph Melenhorst
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 113:2238-44. 2009
    ..These data suggest that concomitant examination of bone marrow specimens in patients with myeloid leukemias might yield more definitive information in the search for immunologic prognosticators of clinical outcome...
  11. pmc T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy
    Elaine M Sloand
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 117:2691-9. 2011
    ..Thus, our results suggest that WT1 is one of the antigens that triggers T cell-mediated myelosuppression in MDS...
  12. pmc Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland Hematology Service, Oncology Center, Hospital Sao Jose, Beneficencia Portuguesa, Sao Paulo, Brazil
    Am J Hematol 89:467-9. 2014
    ..Although h-ATG may be utilized in the salvage setting, the overall response rate probably will be lower than when h-ATG is used as initial treatment...
  13. pmc Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, 20892 1202, USA
    Haematologica 95:1075-80. 2010
    ..Flow cytometry has allowed for sensitive and precise measurement of glycosylphosphatidylinositol-anchor protein-deficient red blood cells and neutrophils in severe aplastic anemia...
  14. pmc Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab
    Elaine M Sloand
    National Heart Lung and Blood Instititute, NIH, Bethesda, MD 20892, USA
    Haematologica 95:382-7. 2010
    ....
  15. pmc Granulocyte transfusions in severe aplastic anemia: an eleven-year experience
    Karen Quillen
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Haematologica 94:1661-8. 2009
    ..Infections, particularly those caused by invasive fungi, are a major cause of death in patients with severe aplastic anemia. The purpose of this study was to analyze our experience with granulocyte transfusions in such patients...
  16. pmc Horse versus rabbit antithymocyte globulin in acquired aplastic anemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    N Engl J Med 365:430-8. 2011
    ..Although horse ATG is the standard therapy, rabbit ATG is more potent in depleting peripheral-blood lymphocytes and is preferred in other clinical circumstances...
  17. pmc Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bldg 10 CRC 4 5230, Bethesda, MD 20892, USA
    J Clin Oncol 28:5166-73. 2010
    ..Because of the toxicities associated with h-ATG/CsA, we investigated an alternative regimen with alemtuzumab in MDS...
  18. pmc Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    J Pediatr 153:814-9. 2008
    ....
  19. pmc Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers
    Pratip K Chattopadhyay
    Immunotechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cytometry A 73:1001-9. 2008
    ....
  20. pmc Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, 10 Center Dr, Bldg 10 CRC, Room 3 5140, MSC 1202, Bethesda, MD 20892 1202, USA
    JAMA 304:1358-64. 2010
    ..Variations in telomere length have been reported in severe aplastic anemia but their clinical significance is unknown...
  21. doi request reprint Aplastic anemia: therapeutic updates in immunosuppression and transplantation
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Hematology Am Soc Hematol Educ Program 2012:292-300. 2012
    ..The most recent advances in HSCT and IST in SAA are discussed in this review...
  22. pmc Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Leuk Res 36:982-9. 2012
    ..Knockdown" of cyclin D1 by RNA interference decreased trisomy 8 cell growth, suggesting that this might be a therapeutic target in MDS...
  23. pmc Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients
    Elaine M Sloand
    National Heart Lung and Blood Institute, Hematology Branch, Office of Biostatistics Research, Division of Prevention and Population Sciences, National Institutes of Health, Bethesda, MD 20892 1260, USA
    Exp Hematol 36:1616-24. 2008
    ..We hypothesized that suPAR, prevents the interaction of urokinase with membrane-anchored uPAR on residual normal cells...
  24. pmc Aplastic anemia
    Neal S Young
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1202, USA
    Curr Opin Hematol 15:162-8. 2008
    ....
  25. pmc Th17 immune responses contribute to the pathophysiology of aplastic anemia
    Regis Peffault De Latour
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 116:4175-84. 2010
    ..01) and more Treg cells (P < .05) at day 10 after lymph node infusion. Th17 immune responses contribute to AA pathophysiology, especially at the early stage during disease progression...
  26. pmc Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Br J Haematol 144:206-16. 2009
    ..In the era of IST, the baseline ARC and ALC together serve as a simple predictor of response following IST, which should guide in risk stratification among patients with SAA...
  27. ncbi request reprint The clonal composition of human CD4+CD25+Foxp3+ cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol Methods 321:107-20. 2007
    ..Clonotypes shared between the CD4+CD25+Foxp3+ and CD4+CD25+Foxp3- subsets were observed in all 3 UCB and in one adult PBMCs, suggesting that naïve and memory CD4+ T(R) can share the same clonotypes as CD4+ non-T(R) in humans...
  28. pmc Eltrombopag and improved hematopoiesis in refractory aplastic anemia
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 367:11-9. 2012
    ..Thrombopoietin may increase the number of hematopoietic stem cells and progenitor cells...
  29. pmc Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes
    Xingmin Feng
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Haematologica 96:602-6. 2011
    ..Future studies focusing on cytokines that better discriminate these two entities such as thrombopoietin and chemokine (C-C motif) ligand 3 may be useful tools in clinical practice...
  30. pmc Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades
    Jessica M Valdez
    Howard Hughes Medical Institute, National Institutes of Health Research Scholars Program, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
    Clin Infect Dis 52:726-35. 2011
    ..However, little is known about the current patterns of infections and the impact of advances in anti-infective therapy on survival in SAA...
  31. ncbi request reprint Mobilization, collection, and immunomagnetic selection of peripheral blood CD34 cells in recovered aplastic anemia patients
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, and the Mark O Hatfield Clinical Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 47:1250-3. 2007
    ..Even patients who have clinically recovered from aplastic anemia have diminished hematopoietic progenitor cells, so the practicability of PBPC mobilization in these individuals is unknown...
  32. pmc Current concepts in the pathophysiology and treatment of aplastic anemia
    Neal S Young
    Hematology Branch, National Heart, Lung, and Blood Institute NIH, 10 Center Drive, Bldg 10 CRC, Rm 3E 5140, Bethesda, MD 20892 1202, USA
    Blood 108:2509-19. 2006
    ..Recent results with alternative sources of stem cells and a variety of conditioning regimens to achieve their engraftment have been promising, with survival in small pediatric case series rivaling conventional transplantation results...
  33. ncbi request reprint Severe menorrhagia associated with thrombocytopenia
    Eric D Levens
    Reproductive Endocrinology and Infertility, National Institutes of Health, Walter Reed Army Medical Center, National Naval Medical Center, Uniformed Services University of the Health Sciences, Maryland, USA
    Obstet Gynecol 110:913-7. 2007
  34. pmc How I treat acquired aplastic anemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    Blood 120:1185-96. 2012
    ....
  35. ncbi request reprint Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab)
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann Intern Med 144:181-5. 2006
    ..Most patients respond to some form of immunosuppressive treatment, but few prospective clinical trials have been performed...
  36. pmc Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria
    Jeremy Pantin
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland Division of Hematology and Oncology, Department of Medicine, Georgia Regents University, Augusta, Georgia
    Biol Blood Marrow Transplant 20:1435-9. 2014
    ..8%) survived, all without any evidence of PNH, transfusion independent, and off anticoagulation. Allogeneic reduced-intensity HCT remains a curative therapeutic option for PNH patients who are not candidates for eculizumab treatment. ..
  37. ncbi request reprint Infections in patients with aplastic anemia
    Jessica M Valdez
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD, USA
    Semin Hematol 46:269-76. 2009
    ..The specific immune impairment and current treatment parameters for each of these classes of infection will also be discussed...
  38. ncbi request reprint Apparent hemolysis following intravenous antithymocyte globulin treatment in a patient with marrow failure and a paroxysmal nocturnal hemoglobinuria clone
    Minh Ha Tran
    Mark O Hatfield Clinical Research Center, Warren G Magnuson Clinical Center, Department of Transfusion Medicine, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 46:1244-7. 2006
    ..We report a case of apparent ATG-related hemolysis in a patient with aplastic anemia and a paroxysmal nocturnal hemoglobinuria (PNH) clone...
  39. pmc Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers
    J Joseph Melenhorst
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol Methods 338:31-9. 2008
    ....
  40. doi request reprint Aplastic anemia: what have we learned from animal models and from the clinic
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md Electronic address
    Semin Hematol 50:156-64. 2013
    ..In this review, the evolution of murine models and their clinical relevance in AA are discussed. ..
  41. pmc Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis
    Michail S Lionakis
    Clinical Mycology Unit, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 8:e1002865. 2012
    ..Thus, neutrophil Ccr1 amplifies late renal immunopathology and increases mortality in invasive candidiasis by mediating excessive recruitment of neutrophils from the blood to the target organ...
  42. pmc Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions
    Jennifer Daniel-Johnson
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, and the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
    Transfusion 49:1845-9. 2009
    ..Reported cases have involved group O donors. Two cases of PLT-mediated HTRs associated with the same group A plateletpheresis component, collected from a donor taking high doses of probiotics are reported...
  43. pmc Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center VRC, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Bethesda, MD, USA
    Blood 112:2826-35. 2008
    ..Finally, these data may help account for the nonprogressive nature of nonpathogenic SIV infection in sooty mangabeys...
  44. pmc Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations
    Natalie E R Beveridge
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
    Eur J Immunol 37:3089-100. 2007
    ..Overall, these data strongly support the use of MVA85A in humans as a boosting agent to expand polyfunctional M.tb-specific CD4(+) T cells capable of significant secondary responses...